Vanda Pharmaceuticals Inc.
VNDA
$5.25
-$0.08-1.50%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.71% | 65.60% | -525.11% | 16.98% | 7.75% |
| Total Depreciation and Amortization | 5.05% | -39.84% | 185.58% | -28.94% | 2.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.54% | -97.37% | 3,567.51% | 52.57% | -36.98% |
| Change in Net Operating Assets | 419.35% | -360.58% | 137.24% | -153.03% | 900.52% |
| Cash from Operations | 38.13% | -70.71% | 6.98% | -107.36% | 53.99% |
| Capital Expenditure | 14.03% | -116.67% | 36.65% | 46.15% | 31.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.22% | -54.51% | 108.93% | 243.76% | -133.77% |
| Cash from Investing | 67.09% | -54.90% | 110.03% | 239.90% | -134.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -10.31% | -21.25% | -23.79% | -21.65% | -3.91% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -10.31% | -21.25% | -23.79% | -21.65% | 67.90% |
| Foreign Exchange rate Adjustments | 36.84% | -385.00% | 111.11% | -234.33% | 173.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 106.00% | -307.82% | 235.29% | 64.43% | -425.03% |